Publications by authors named "Alshad S Lalani"

40Publications

Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.

Cancer Cell 2020 02 23;37(2):183-199.e5. Epub 2020 Jan 23.

Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2019.12.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301608PMC
February 2020

The calcium-sensing receptor: A novel target for treatment and prophylaxis of neratinib-induced diarrhea.

Pharmacol Res Perspect 2019 10 13;7(5):e00521. Epub 2019 Sep 13.

Department of Surgery Yale University School of Medicine New Haven CT USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/prp2.521DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743423PMC
October 2019

Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody .

Oncotarget 2019 Aug 20;10(49):5120-5122. Epub 2019 Aug 20.

Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.27162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707946PMC
August 2019

Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells.

Oncogene 2019 07 28;38(30):5890-5904. Epub 2019 Jun 28.

Department of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41388-019-0849-8
Publisher Site
http://dx.doi.org/10.1038/s41388-019-0849-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133220PMC
July 2019

Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα and Gα and kill uveal melanoma cells.

Cancer Biol Ther 2019 20;20(5):700-710. Epub 2018 Dec 20.

a Departments of Biochemistry and Molecular Biology , Virginia Commonwealth University , Richmond , VA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2018.1551747DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606002PMC
July 2020

Neratinib augments the lethality of [regorafenib + sildenafil].

J Cell Physiol 2019 04 10;234(4):4874-4887. Epub 2018 Sep 10.

Departments of Biochemistry and Molecular Biology, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jcp.27276
Publisher Site
http://dx.doi.org/10.1002/jcp.27276DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322207PMC
April 2019

Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition.

Cancer Biol Ther 2019 5;20(2):157-168. Epub 2018 Sep 5.

a Departments of Biochemistry and Molecular Biology , Virginia Commonwealth University , Richmond , VA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2018.1507665DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343717PMC
April 2020

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.

Cancer Biol Ther 2018 06 6;19(6):525-533. Epub 2018 Mar 6.

a Department of Biochemistry and Molecular Biology , Virginia Commonwealth University , Richmond , VA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2018.1436024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927661PMC
June 2018

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody .

Oncotarget 2017 Oct 9;8(52):90262-90277. Epub 2017 Oct 9.

Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/21660
Publisher Site
http://dx.doi.org/10.18632/oncotarget.21660DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685747PMC
October 2017

Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.

PLoS One 2014 13;9(11):e112371. Epub 2014 Nov 13.

Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York, United States of America; Department of Cancer Pathology & Prevention, Roswell Park Cancer Institute Division, University at Buffalo, Buffalo, New York, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0112371PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231048PMC
August 2015

The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone.

Cancer Res 2009 Feb 27;69(3):940-7. Epub 2009 Jan 27.

Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/content/69/3/940.full.pdf
Web Search
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-08-0676DOI Listing
February 2009

A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.

Clin Cancer Res 2008 Nov;14(21):7110-5

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-08-0483DOI Listing
November 2008

Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer.

Clin Cancer Res 2007 Apr;13(7):2216-25

Novacea, Inc., South San Francisco, California and KuDOS Pharmaceuticals Ltd., Cambridge, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-2427DOI Listing
April 2007